Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Tal Engel; Uri Kopylov

doi:10.1177/2040622316653306

Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Tal Engel, Uri Kopylov^*

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

Original language	English
Pages (from-to)	208-214
Number of pages	7
Journal	Therapeutic Advances in Chronic Disease
Volume	7
Issue number	4
DOIs	https://doi.org/10.1177/2040622316653306
State	Published - 1 Jul 2016

Keywords

Crohn’s disease
interleukin 12/23p40 inhibitor
ustekinumab

Access to Document

10.1177/2040622316653306

Cite this

@article{3b16c3aef977418eb72b80135d012df2,

title = "Ustekinumab in Crohn{\textquoteright}s disease: evidence to date and place in therapy",

abstract = "Crohn{\textquoteright}s disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.",

keywords = "Crohn{\textquoteright}s disease, interleukin 12/23p40 inhibitor, ustekinumab",

author = "Tal Engel and Uri Kopylov",

note = "Publisher Copyright: {\textcopyright} 2016, {\textcopyright} The Author(s), 2016.",

year = "2016",

month = jul,

day = "1",

doi = "10.1177/2040622316653306",

language = "אנגלית",

volume = "7",

pages = "208--214",

journal = "Therapeutic Advances in Chronic Disease",

issn = "2040-6223",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Ustekinumab in Crohn’s disease

T2 - evidence to date and place in therapy

AU - Engel, Tal

AU - Kopylov, Uri

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Crohn’s disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

AB - Crohn’s disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

KW - Crohn’s disease

KW - interleukin 12/23p40 inhibitor

KW - ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84978060502&partnerID=8YFLogxK

U2 - 10.1177/2040622316653306

DO - 10.1177/2040622316653306

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:84978060502

SN - 2040-6223

VL - 7

SP - 208

EP - 214

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

IS - 4

ER -

Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this